4 results
Introduction to the Guideline, and General Principles of Acute Migraine Management
- Irene Worthington, Tamara Pringsheim, Marek J. Gawel, Jonathan Gladstone, Paul Cooper, Esma Dilli, Michel Aube, Elizabeth Leroux, Werner J. Becker, on behalf of the Canadian Headache Society Acute Migraine Treatment Guideline Development Group
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 40 / Issue S3 / September 2013
- Published online by Cambridge University Press:
- 01 July 2015, pp. S4-S9
-
- Article
-
- You have access Access
- Export citation
-
Objectives:
To provide an overview of the objectives and target population of the guideline, and to review the general principles of acute pharmacological migraine therapy.
Methods:A general literature review and several consensus groups were used to formulate an expert consensus for the general use of acute migraine medications.
Results:The objective of the guideline is to assist the physician in choosing an appropriate acute migraine medication for an individual with migraine, and thereby to reduce migraine-related disability. The target population includes adults with episodic migraine (patients with migraine headache < 15 days/month). This guideline is intended primarily for physicians who treat patients with migraine. Other health professionals may also find this guideline helpful. Acute migraine therapy should be considered for the great majority of patients with migraine. A specific acute medication is chosen based on evidence for efficacy, tolerability, migraine attack severity, patient preference, and on the presence of co-existing disorders. General principles of acute migraine therapy include that the response of a patient to any given medication cannot be predicted with certainty, and that treatment early in the attack is generally more effective than treatment later once the migraine attack is fully developed. A suitable treatment approach (stratified or stepped approaches) and drug formulation (injection, tablet, wafer, powdered formulation, or nasal spray) should be chosen based on patient clinical features. Excessively frequent use of acute medications (medication overuse) should be avoided. Two or more acute medications can be combined if necessary.
Conclusions:This guideline provides evidence-based advice on the use of acute medications for migraine, and should provide useful guidance for acute migraine therapy to both health professionals and patients.
Targeted Review: Medications for Acute Migraine Treatment
- Irene Worthington, Tamara Pringsheim, Marek J. Gawel, Jonathan Gladstone, Paul Cooper, Esma Dilli, Michel Aube, Elizabeth Leroux, Werner J. Becker, on behalf of the Canadian Headache Society Acute Migraine Treatment Guideline Development Group
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 40 / Issue S3 / September 2013
- Published online by Cambridge University Press:
- 01 July 2015, pp. S10-S32
-
- Article
-
- You have access Access
- Export citation
-
Objective:
To assess the evidence base for drugs used for acute treatment of episodic migraine (headache on < 14 days a month) in Canada.
Methods:A detailed search strategy was employed to find relevant published clinical trials of drugs used in Canada for the acute treatment of migraine in adults. Primarily meta-analyses and systematic reviews were included. Where these were not available for a drug or were out of date, individual clinical trial reports were utilized. Only double-blind randomized clinical trials with placebo or active drug controls were included in the analysis. Recommendations and levels of evidence were graded according to the principles of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group, using a consensus group.
Results:Eighteen acute migraine medications and two adjunctive medications were evaluated. Twelve acute medications received a strong recommendation with supporting high quality evidence for use in acute migraine therapy (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, ASA, ibuprofen, naproxen sodium, diclofenac potassium, and acetaminophen). Four acute medications received a weak recommendation for use with low or moderate quality evidence (dihydroergotamine, ergotamine, codeine-containing combination analgesics, and tramadol-containing combination analgesics). Three of these medications were NOT recommended for routine use (ergotamine, and codeine- and tramadol-containing medications), and strong recommendations were made to avoid use of butorphanol and butalbital-containing medications. Both metoclopramide and domperidone received a strong recommendation for use with acute migraine attack medications where necessary.
Conclusion:Our targeted review formulated recommendations for the available acute medications for migraine treatment according to the GRADE method. This should be helpful for practitioners who prescribe medications for acute migraine treatment.
Canadian Headache Society Guideline: Acute Drug Therapy for Migraine Headache
- Irene Worthington, Tamara Pringsheim, Marek J. Gawel, Jonathan Gladstone, Paul Cooper, Esma Dilli, Michel Aube, Elizabeth Leroux, Werner J. Becker, on behalf of the Canadian Headache Society Acute Migraine Treatment Guideline Development Group
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 40 / Issue S3 / September 2013
- Published online by Cambridge University Press:
- 01 July 2015, pp. S1-S3
-
- Article
-
- You have access Access
- Export citation
-
Objectives:
The primary objective of this guideline is to assist the practitioner in choosing an appropriate acute medication for an individual with migraine, based on current evidence in the medical literature and expert consensus. It is focused on patients with episodic migraine (headache on < 14 days a month).
Methods:A detailed search strategy was used to find relevant meta-analyses, systematic reviews and randomized double-blind controlled trials. Recommendations were graded with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group, using a consensus group. In addition, a general literature review and expert consensus were used for aspects of acute therapy for which randomized controlled trials are not available.
Results:Twelve acute medications received a strong recommendation for use in acute migraine therapy (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, ASA, ibuprofen, naproxen sodium, diclofenac potassium, and acetaminophen). Four received a weak recommendation for use (dihydroergotamine, ergotamine, codeine-containing combination analgesics, and tramadol-containing combination analgesics). Three of these were NOT recommended for routine use (ergotamine, and codeine- and tramadol-containing medications). Strong recommendations were made to avoid use of butorphanol and butalbital-containing medications. Metoclopramide and domperidone were strongly recommended for use where necessary. Our analysis also resulted in the formulation of eight general acute migraine treatment strategies. These were grouped into: 1) two mild-moderate attack strategies, 2) two moderate-severe attack or NSAID failure strategies, 3) three refractory migraine strategies, and 4) a vasoconstrictor unresponsive-contraindicated strategy. Additional strategies were developed for menstrual migraine, migraine during pregnancy, and migraine during lactation.
Conclusion:This guideline provides evidence-based advice on acute pharmacological migraine therapy, and should be helpful to both health professionals and patients. The available medications have been organized into a series of strategies based on patient clinical features. These strategies may help practitioners make appropriate acute medication choices for patients with migraine.
Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient
- Irene Worthington, Tamara Pringsheim, Marek J. Gawel, Jonathan Gladstone, Paul Cooper, Esma Dilli, Michel Aube, Elizabeth Leroux, Werner J. Becker, on behalf of the Canadian Headache Society Acute Migraine Treatment Guideline Development Group
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 40 / Issue S3 / September 2013
- Published online by Cambridge University Press:
- 01 July 2015, pp. S33-S62
-
- Article
-
- You have access Access
- Export citation
-
Background:
In our targeted review (Section 2), 12 acute medications received a strong recommendation for use in acute migraine therapy while four received a weak recommendation for use. Strong recommendations were made to avoid use of two other medications, except for exceptional circumstances. Two anti-emetics received strong recommendations for use as needed.
Objective:To organize the available acute migraine medications into acute migraine treatment strategies in order to assist the practitioner in choosing a specific medication(s) for an individual patient.
Methods:Acute migraine treatment strategies were developed based on the targeted literature review used for the development of this guideline (Section 2), and a general literature review. Expert consensus groups were used to refine and validate these strategies.
Results:Based on evidence for drug efficacy, drug side effects, migraine severity, and coexistent medical disorders, our analysis resulted in the formulation of eight general acute migraine treatment strategies. These could be grouped into four categories: 1) two mild-moderate attack strategies, 2) two moderate-severe attack or NSAID failure strategies, 3) three refractory migraine strategies, and 4) a vasoconstrictor unresponsive-contraindicated strategy. In addition, strategies were developed for menstrual migraine, migraine during pregnancy, and migraine during lactation. The eight general treatment strategies were coordinated with a “combined acute medication approach” to therapy which used features of both the “stratified” and the “step care across attacks” approaches to acute migraine management.
Conclusions:The available medications for acute migraine treatment can be organized into a series of strategies based on patient clinical features. These strategies may help practitioners make appropriate acute medication choices for patients with migraine.